Jim Mclean


Jim is an Auckland-based company director who is currently the Chair of Aroa Biosurgery Ltd., Prevar Ltd., Infotools Ltd.,and Pictor Ltd., Mr McLean was previously an Executive Director of Genesis Research and prior to that, a partner with Ernst & Young. He is a Member of the Institute of Directors and is an Associate Chartered Accountant.

Phil McCaw B.B.S.,

Non Executive Director

Phil holds a Bachelor of Business Studies from Massey University majoring in Accounting, Finance and Information Technology. Phil qualified as a chartered accountant and was a member of the New Zealand Society of Accountants from 1991 through to 1998. Phil has served on the Boards of numerous early stage companies since 1997.

Brian Ward

Managing Director

Brian has held senior corporate roles in life sciences and health care companies over the last 20 years. He is a graduate from Massey University with a Bachelors degree in Veterinary Science, a Member of the Royal College of Veterinary Surgeons (UK), and holds a Masters degree in Business Administration graduating with distinction. He has extensive management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, has sat on a number of government and industry expert panels and is a member of the Massey University Foundation and Equine Research Boards.

John Pinion II

Independent Director

John Pinion has over 25 years of global experience providing executive leadership and expertise in engineering, quality, manufacturing management of biologic, pharmaceutical and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. Mr. Pinion provides leadership for Ultragenyx’s translational sciences functions to include Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance, Validation, and CMC Analytical Development and QC.

As a key member of Ultragenyx’s executive leadership team reporting directly to the organization’s CEO, he also contributes to ongoing business development, clinical development and commercial and strategic planning activities.

In the ten years prior to joining Ultragenyx, Mr. Pinion held roles of increasing responsibility at Genentech (subsequently Roche when Genentech was acquired), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland.

Previous to Genentech, Mr. Pinion spent 17 years in operational and senior leadership roles in Baxter International’s Renal, Bioscience, Parenterals and Device divisions.

John currently sits on the Board of Directors and serves as the Chair of the Audit and Risk Committee of Aroa Biosurgery Ltd, a privately-held soft tissue repair company commercializing regenerative tissue substitutes based in Auckland, New Zealand. He holds a B.S. in Mechanical Engineering from West Virginia University and lives in Northern California with his wife and two sons.

Steve Engle

Independent Director

Steve Engle brings deep experience in US capital markets, a record of achievement with big pharma partnering and established links with the US FDA. As a former CEO of NASDAQ-listed companies Xoma and La Jolla Pharmaceuticals, he brings wide networks in the US and European biotech industries. He is a current CEO of Averigon Consulting, a leading advisory firm to the US life sciences industry.